Hybridize Therapeutics
PrivateLast Round
Strategic
Feb 9, 2022
Total Funding Raised
$315,000
Company Overview
Hybridize Therapeutics is a biotechnology company developing kidney-targeted RNA-based therapies for patients with acute and chronic kidney diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hybridize Therapeutics Comparables
Compare Hybridize Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Borealis Biosciences | 82% | |
| Judo Bio | 77% | |
| Asahi Kasei | 75% |
Hybridize Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 9, 2022 | ||||
| Accelerator | Jun 29, 2018 |
Hybridize Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mibiton Foundation | Debt |
| Netherlands Organization for Scientific Research | Debt |
| Life Sciences @ Work Venture Challenge | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 124% MoM, reaching 1.3K.
- Jan 20, 2026
Monthly visitors grew 41% MoM.
Hybridize Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hybridize Therapeutics's valuation, stock price, and market status.
Is Hybridize Therapeutics a public or private company?
Hybridize Therapeutics is a private company.
What is the current stock price of Hybridize Therapeutics?
Hybridize Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Hybridize Therapeutics worth (valuation)?
Valuation information for Hybridize Therapeutics is not publicly available.
Can I buy Hybridize Therapeutics stock?
Hybridize Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Hybridize Therapeutics's last funding round?
Funding round information for Hybridize Therapeutics is not publicly available.
Who are the main investors in Hybridize Therapeutics?
Investor information for Hybridize Therapeutics is not publicly disclosed.
Will Hybridize Therapeutics IPO soon?
No public IPO plans have been announced for Hybridize Therapeutics.
How can I track Hybridize Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hybridize Therapeutics's secondary market activity and sign up for updates.